Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:LLY
- CUSIP: 53245710
- Web: www.lilly.com
- Market Cap: $89.52 billion
- Outstanding Shares: 1,056,300,000
- 50 Day Moving Avg: $82.14
- 200 Day Moving Avg: $81.04
- 52 Week Range: $64.18 - $86.72
Sales & Book Value:
- Trailing P/E Ratio: 40.73
- Foreward P/E Ratio: 19.26
- P/E Growth: 1.69
- Annual Revenue: $21.59 billion
- Price / Sales: 4.15
- Book Value: $13.28 per share
- Price / Book: 6.38
- Annual Dividend: $2.08
- Dividend Yield: 2.5%
- EBIDTA: $5.64 billion
- Net Margins: 10.13%
- Return on Equity: 26.64%
- Return on Assets: 10.35%
- Debt-to-Equity Ratio: 0.54%
- Current Ratio: 1.24%
- Quick Ratio: 0.86%
- Average Volume: 3.56 million shs.
- Beta: 0.35
- Short Ratio: 2.62
Frequently Asked Questions for Eli Lilly and Company (NYSE:LLY)
What is Eli Lilly and Company's stock symbol?
Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?
Eli Lilly and Company declared a quarterly dividend on Monday, June 19th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share on Friday, September 8th. This represents a $2.08 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date is Friday, August 11th. View Eli Lilly and Company's Dividend History.
How were Eli Lilly and Company's earnings last quarter?
Eli Lilly and Company (NYSE:LLY) announced its earnings results on Tuesday, April, 25th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.96 by $0.02. The business had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.22 billion. Eli Lilly and Company had a net margin of 10.13% and a return on equity of 26.64%. Eli Lilly and Company's revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.83 earnings per share. View Eli Lilly and Company's Earnings History.
When will Eli Lilly and Company make its next earnings announcement?
What guidance has Eli Lilly and Company issued on next quarter's earnings?
Eli Lilly and Company updated its FY17 earnings guidance on Tuesday, April, 25th. The company provided earnings per share (EPS) guidance of $4.05-4.15 for the period, compared to the Thomson Reuters consensus estimate of $4.10. The company issued revenue guidance of $21.8-22.3 billion, compared to the consensus revenue estimate of $22.10 billion.
Where is Eli Lilly and Company's stock going? Where will Eli Lilly and Company's stock price be in 2017?
16 equities research analysts have issued 12 month target prices for Eli Lilly and Company's shares. Their predictions range from $73.00 to $100.00. On average, they anticipate Eli Lilly and Company's share price to reach $88.67 in the next year. View Analyst Ratings for Eli Lilly and Company.
What are analysts saying about Eli Lilly and Company stock?
Here are some recent quotes from research analysts about Eli Lilly and Company stock:
- 1. According to Zacks Investment Research, "Lilly’s presence across a wide range of therapeutic areas and its animal health business provide support in the face of generic competition. Lilly also expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. The stock has risen this year, outperforming the return from the large cap pharma industry. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets. Meanwhile, the recent high-profile pipeline setbacks are an investor concern. Estimates have risen slightly ahead of the company’s Q2 release. The company has a mixed record of earnings surprises in recent quarters. " (7/17/2017)
- 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
- 3. UBS AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)
Who are some of Eli Lilly and Company's key competitors?
Some companies that are related to Eli Lilly and Company include Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Abbott Laboratories (ABT), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Patheon NV (PTHN), Taro Pharmaceutical Industries (TARO), Catalent (CTLT), Akorn (AKRX) and Opko Health (OPK).
Who are Eli Lilly and Company's key executives?
Eli Lilly and Company's management team includes the folowing people:
- David A. Ricks, Chairman of the Board, President, Chief Executive Officer
- Derica W. Rice, Chief Financial Officer, Executive Vice President - Global Services
- Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories
- Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
- Michael J. Harrington, Senior Vice President, General Counsel
- Stephen F. Fry, Senior Vice President - Human Resources and Diversity
- Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
- Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology
- Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications
- Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications
Who owns Eli Lilly and Company stock?
Eli Lilly and Company's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Lilly Endowment Inc. (11.76%), Fisher Asset Management LLC (0.28%), Beutel Goodman & Co Ltd. (0.24%), US Bancorp DE (0.22%), Bank of Montreal Can (0.14%) and Hexavest Inc. (0.13%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and Company.
Who sold Eli Lilly and Company stock? Who is selling Eli Lilly and Company stock?
Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including Lilly Endowment Inc., NN Investment Partners Holdings N.V., Bedrijfstakpensioenfonds Voor DE Media PNO, Hexavest Inc., OLD National Bancorp IN, Exxonmobil Investment Management Inc. TX, Grassi Investment Management and Park National Corp OH. Company insiders that have sold Eli Lilly and Company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and Company.
Who bought Eli Lilly and Company stock? Who is buying Eli Lilly and Company stock?
Eli Lilly and Company's stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Fisher Asset Management LLC, Beutel Goodman & Co Ltd., Mn Services Vermogensbeheer B.V., National Pension Service, Atalanta Sosnoff Capital LLC, Handelsbanken Fonder AB and BKD Wealth Advisors LLC. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and Company.
How do I buy Eli Lilly and Company stock?
Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eli Lilly and Company's stock price today?
MarketBeat Community Rating for Eli Lilly and Company (NYSE LLY)MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Eli Lilly and Company stock can currently be purchased for approximately $84.75.
Consensus Ratings for Eli Lilly and Company (NYSE:LLY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 4 Hold Ratings, 11 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.63)|
|Consensus Price Target: ||$88.67 (4.62% upside)|
Analysts' Ratings History for Eli Lilly and Company (NYSE:LLY)
(Data available from 7/20/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/17/2017||Deutsche Bank AG||Reiterated Rating||Buy||$90.00 -> $91.00||Low|
|7/13/2017||Jefferies Group LLC||Reiterated Rating||Buy||$93.00 -> $96.00||Low|
|7/4/2017||Citigroup Inc.||Reiterated Rating||Buy||$100.00||Low|
|7/4/2017||Barclays PLC||Boost Price Target||Overweight||$85.00 -> $90.00||Low|
|5/21/2017||Sanford C. Bernstein||Reiterated Rating||Outperform||$88.00||Medium|
|5/16/2017||Goldman Sachs Group, Inc. (The)||Reiterated Rating||Conviction-Buy -> Buy||$92.00||High|
|4/29/2017||BMO Capital Markets||Reiterated Rating||Underperform||$71.00 -> $73.00||Low|
|4/27/2017||Argus||Downgrade||Buy -> Hold||$64.18 -> $81.00||Low|
|4/19/2017||Credit Suisse Group||Reiterated Rating||Outperform||$87.00||Low|
|4/17/2017||Piper Jaffray Companies||Reiterated Rating||Buy||$100.00||Medium|
|4/17/2017||Cowen and Company||Boost Price Target||Outperform||$85.00 -> $95.00||Medium|
|4/17/2017||Morgan Stanley||Downgrade||Overweight -> Equal Weight||$82.00||High|
|3/20/2017||Leerink Swann||Reiterated Rating||Outperform||Low|
|11/26/2016||J P Morgan Chase & Co||Reiterated Rating||Overweight||N/A|
|11/25/2016||Atlantic Securities||Downgrade||Overweight -> Neutral||N/A|
|10/27/2016||Societe Generale||Reiterated Rating||Hold||$78.00||N/A|
|6/15/2016||SunTrust Banks, Inc.||Reiterated Rating||Buy||N/A|
|2/4/2016||Berenberg Bank||Boost Price Target||Buy||$105.00 -> $106.00||N/A|
|12/22/2015||Bank of America Corporation||Reiterated Rating||Buy||$104.00 -> $108.00||N/A|
Earnings History for Eli Lilly and Company (NYSE:LLY)Earnings History by Quarter for Eli Lilly and Company (NYSE LLY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/25/2017||Q1 17||$0.96||$0.98||$5.22 billion||$5.23 billion||View||N/A|
|1/31/2017||Q416||$0.98||$0.95||$5.54 billion||$5.76 billion||View||N/A|
|10/25/2016||Q316||$0.96||$0.88||$4.23 billion||$5.19 billion||View||Listen|
|7/26/2016||Q216||$0.86||$0.86||$5.14 billion||$5.40 billion||View||Listen|
|4/26/2016||Q116||$0.85||$0.83||$4.82 billion||$4.87 billion||View||Listen|
|1/28/2016||Q415||$0.78||$0.78||$5.33 billion||$5.38 billion||View||Listen|
|10/22/2015||Q315||$0.76||$0.89||$4.99 billion||$4.96 billion||View||Listen|
|7/23/2015||Q215||$0.74||$0.90||$4.89 billion||$4.98 billion||View||Listen|
|4/23/2015||Q115||$0.76||$0.87||$4.62 billion||$4.64 billion||View||N/A|
|1/30/2015||Q414||$0.74||$0.75||$5.21 billion||$5.12 billion||View||N/A|
|10/23/2014||Q314||$0.66||$0.66||$4.83 billion||$4.88 billion||View||Listen|
|7/24/2014||Q214||$0.66||$0.68||$4.88 billion||$4.94 billion||View||N/A|
|4/24/2014||Q114||$0.70||$0.70||$4.78 billion||$4.68 billion||View||N/A|
|1/30/2014||Q413||$0.72||$0.74||$5.46 billion||$5.81 billion||View||Listen|
|10/23/2013||Q313||$1.04||$1.11||$5.76 billion||$5.77 billion||View||N/A|
|7/24/2013||Q2 2013||$1.01||$1.16||$5.82 billion||$5.93 billion||View||N/A|
|4/24/2013||Q1 2013||$1.05||$1.14||$5.66 billion||$5.60 billion||View||N/A|
|1/29/2013||Q4 2012||$0.82||$0.85||$5.78 billion||$5.96 billion||View||N/A|
Earnings Estimates for Eli Lilly and Company (NYSE:LLY)
2017 EPS Consensus Estimate: $4.11
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Eli Lilly and Company (NYSE:LLY)
|Dividend Growth:||1.30% (3 Year Average)|
|Payout Ratio:||100.48% (Trailing 12 Months of Earnings) |
50.49% (Based on This Year's Estimates)
47.27% (Based on Next Year's Estimates)
|Track Record:||2 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Eli Lilly and Company (NYSE LLY)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Eli Lilly and Company (NYSE:LLY)
Insider Ownership Percentage: 0.20%Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)
Institutional Ownership Percentage: 75.47%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/22/2017||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$84.43||$17,730,300.00|| |
|6/20/2017||Lilly Endowment Inc||Major Shareholder||Sell||215,000||$83.05||$17,855,750.00|| |
|6/12/2017||Melissa S Barnes||Insider||Sell||1,900||$80.78||$153,482.00|| |
|6/9/2017||Michael J Harrington||VP||Sell||22,833||$79.97||$1,825,955.01|| |
|5/4/2017||Enrique A Conterno||SVP||Sell||25,000||$82.76||$2,069,000.00|| |
|3/30/2017||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$84.67||$17,780,700.00|| |
|2/17/2017||Lilly Endowment Inc||Major Shareholder||Sell||230,000||$80.27||$18,462,100.00|| |
|2/6/2017||Alfonso G Zulueta||SVP||Sell||15,000||$77.66||$1,164,900.00|| |
|2/3/2017||Derica W Rice||EVP||Sell||11,162||$77.14||$861,036.68|| |
|2/2/2017||Donald A Zakrowski||Insider||Sell||2,000||$77.52||$155,040.00|| |
|2/1/2017||Lilly Endowment Inc||Major Shareholder||Sell||220,000||$77.35||$17,017,000.00|| |
|12/16/2016||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$72.59||$14,518,000.00|| |
|12/16/2016||Melissa S Barnes||Insider||Sell||2,093||$82.23||$172,107.39|| |
|12/16/2016||R David Hoover||Director||Buy||500||$71.85||$35,925.00|| |
|12/16/2016||Susan Mahony||SVP||Sell||20,242||$72.65||$1,470,581.30|| |
|10/5/2016||Maria A Crowe||Insider||Sell||2,248||$81.37||$182,919.76|| |
|8/15/2016||Jackson P Tai||Director||Buy||5,773||$80.43||$464,322.39|| |
|8/12/2016||Jackson P Tai||Director||Buy||2,560||$80.42||$205,875.20|| |
|7/29/2016||Lilly Endowment Inc||Major Shareholder||Sell||205,000||$82.94||$17,002,700.00|| |
|7/28/2016||Donald A Zakrowski||Insider||Sell||1,213||$83.16||$100,873.08|| |
|7/28/2016||Lilly Endowment Inc||Major Shareholder||Sell||240,000||$82.87||$19,888,800.00|| |
|7/12/2016||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$79.54||$16,703,400.00|| |
|7/7/2016||Lilly Endowment Inc||Major Shareholder||Sell||225,000||$79.14||$17,806,500.00|| |
|6/30/2016||Lilly Endowment Inc||Major Shareholder||Sell||215,000||$78.46||$16,868,900.00|| |
|6/29/2016||Lilly Endowment Inc||Major Shareholder||Sell||220,000||$77.86||$17,129,200.00|| |
|6/10/2016||Melissa S Barnes||SVP||Sell||992||$73.77||$73,179.84|| |
|5/31/2016||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$75.12||$15,024,000.00|| |
|5/12/2016||Jackson P Tai||Director||Buy||1,080||$75.75||$81,810.00|| |
|5/12/2016||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$75.86||$14,413,400.00|| |
|5/2/2016||Donald A Zakrowski||CAO||Sell||1,600||$75.86||$121,376.00|| |
|4/29/2016||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$75.44||$13,579,200.00|| |
|4/27/2016||Alfonso G Zulueta||SVP||Sell||12,000||$76.27||$915,240.00|| |
|4/8/2016||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$74.29||$14,858,000.00|| |
|2/5/2016||Stephen F Fry||SVP||Sell||15,230||$78.87||$1,201,190.10|| |
|2/3/2016||David A. Ricks||SVP||Sell||5,733||$77.66||$445,224.78|| |
|2/3/2016||Derica W. Rice||CFO||Sell||10,483||$77.78||$815,367.74|| |
|2/1/2016||Jackson P Tai||Director||Buy||3,170||$78.62||$249,225.40|| |
|1/29/2016||Alfonso G Zulueta||SVP||Sell||5,000||$78.75||$393,750.00|| |
|12/21/2015||Lilly Endowment Inc||Major Shareholder||Sell||205,000||$86.00||$17,630,000.00|| |
|12/15/2015||Lilly Endowment Inc||Major Shareholder||Sell||215,000||$85.60||$18,404,000.00|| |
|12/9/2015||Enrique A Conterno||VP||Sell||25,000||$83.88||$2,097,000.00|| |
|12/2/2015||Lilly Endowment Inc||major shareholder||Sell||210,000||$85.09||$17,868,900.00|| |
|11/20/2015||Lilly Endowment Inc||major shareholder||Sell||205,000||$84.54||$17,330,700.00|| |
|10/29/2015||Lilly Endowment Inc||major shareholder||Sell||200,000||$82.28||$16,456,000.00|| |
|10/9/2015||Lilly Endowment Inc||major shareholder||Sell||215,000||$85.86||$18,459,900.00|| |
|10/5/2015||Lilly Endowment Inc||major shareholder||Sell||260,000||$86.46||$22,479,600.00|| |
|9/18/2015||Lilly Endowment Inc||major shareholder||Sell||250,000||$89.04||$22,260,000.00|| |
|6/10/2015||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$82.39||$17,301,900.00|| |
|6/4/2015||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$77.90||$15,580,000.00|| |
|5/29/2015||Jeffrey N Simmons||SVP||Sell||20,000||$78.08||$1,561,600.00|| |
|5/20/2015||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$73.43||$13,951,700.00|| |
|5/15/2015||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$72.83||$14,566,000.00|| |
|5/8/2015||Lilly Endowment Inc||Major Shareholder||Sell||195,000||$73.28||$14,289,600.00|| |
|5/1/2015||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$73.09||$14,618,000.00|| |
|3/30/2015||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$73.94||$13,309,200.00|| |
|3/23/2015||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$76.97||$14,624,300.00|| |
|3/9/2015||Stephen F Fry||SVP||Sell||4,000||$69.27||$277,080.00|| |
|2/4/2015||David A Ricks||SVP||Sell||3,147||$69.99||$220,258.53|| |
|2/4/2015||Derica W Rice||CFO||Sell||5,316||$70.00||$372,120.00|| |
|2/4/2015||Jan M Lundberg||EVP||Sell||11,085||$70.08||$776,836.80|| |
|2/3/2015||Jan M Lundberg||EVP||Sell||121,711||$70.78||$8,614,704.58|| |
|2/2/2015||David A Ricks||SVP||Sell||4,769||$71.51||$341,031.19|| |
|2/2/2015||Derica W Rice||CFO||Sell||10,068||$71.84||$723,285.12|| |
|12/4/2014||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$71.92||$13,664,800.00|| |
|12/2/2014||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$70.14||$12,625,200.00|| |
|11/13/2014||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$67.73||$13,546,000.00|| |
|11/5/2014||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$67.00||$12,060,000.00|| |
|11/4/2014||Fionnuala M Walsh||SVP||Sell||15,000||$67.00||$1,005,000.00|| |
|11/3/2014||Enrique A Conterno||VP||Sell||5,000||$66.03||$330,150.00|| |
|10/31/2014||Fionnuala M Walsh||SVP||Sell||7,376||$66.58||$491,094.08|| |
|10/31/2014||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$66.40||$12,616,000.00|| |
|10/30/2014||Lilly Endowment Inc||Major Shareholder||Sell||175,000||$66.58||$11,651,500.00|| |
|10/24/2014||Maria A Crowe||Insider||Sell||2,750||$65.77||$180,867.50|| |
|10/6/2014||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$65.63||$13,782,300.00|| |
|10/1/2014||Enrique A Conterno||VP||Sell||5,000||$64.86||$324,300.00|| |
|9/30/2014||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$65.07||$13,014,000.00|| |
|9/10/2014||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$64.77||$13,601,700.00|| |
|9/3/2014||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$63.99||$12,798,000.00|| |
|9/2/2014||Enrique A Conterno||VP||Sell||5,000||$63.60||$318,000.00|| |
|7/29/2014||Lilly Endowment Inc||Major Shareholder||Sell||250,000||$63.03||$15,757,500.00|| |
|7/28/2014||Susan Mahony||SVP||Sell||2,065||$63.30||$130,714.50|| |
|7/25/2014||Enrique A Conterno||VP||Sell||10,000||$63.79||$637,900.00|| |
|7/25/2014||Susan Mahony||SVP||Sell||30,000||$63.90||$1,917,000.00|| |
|7/1/2014||Lilly Endowment Inc||Major Shareholder||Sell||235,000||$62.30||$14,640,500.00|| |
|6/25/2014||Lilly Endowment Inc||Major Shareholder||Sell||245,000||$62.68||$15,356,600.00|| |
|6/20/2014||Lilly Endowment Inc||Major Shareholder||Sell||230,000||$61.55||$14,156,500.00|| |
|6/16/2014||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$58.73||$11,746,000.00|| |
|6/5/2014||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$59.53||$11,310,700.00|| |
|5/21/2014||Lilly Endowment Inc||major shareholder||Sell||230,000||$58.90||$13,547,000.00|| |
|5/12/2014||Jackson Tai||Director||Buy||17,157||$59.19||$1,015,522.83|| |
|5/12/2014||Lilly Endowment Inc||major shareholder||Sell||210,000||$59.33||$12,459,300.00|| |
|5/6/2014||Lilly Endowment Inc||major shareholder||Sell||190,000||$58.79||$11,170,100.00|| |
|4/29/2014||Lilly Endowment Inc||major shareholder||Sell||200,000||$59.43||$11,886,000.00|| |
|4/28/2014||Lilly Endowment Inc||major shareholder||Sell||150,000||$58.64||$8,796,000.00|| |
|8/15/2013||Enrique Conterno||VP||Sell||5,000||$53.79||$268,950.00|| |
|7/29/2013||Jacques Tapiero||SVP||Sell||7,500||$53.74||$403,050.00|| |
|7/15/2013||Enrique A Conterno||VP||Sell||5,000||$51.43||$257,150.00|| |
|6/17/2013||Enrique A Conterno||VP||Sell||5,000||$52.45||$262,250.00|| |
|5/15/2013||Enrique A Conterno||VP||Sell||5,000||$56.15||$280,750.00|| |
|5/10/2013||Jeffrey N Simmons||SVP||Sell||10,000||$54.49||$544,900.00|| |
|3/26/2013||Susan Mahony||SVP||Sell||5,000||$56.00||$280,000.00|| |
Headline Trends for Eli Lilly and Company (NYSE:LLY)
Latest Headlines for Eli Lilly and Company (NYSE:LLY)
Eli Lilly and Company (LLY) Chart for Thursday, July, 20, 2017